| Filed On | Filing |
|---|---|
| 12 Nov 2026 | 8-K: Results of Operations and Financial Condition; Regulation FD Disclosure |
| 28 Sep 2026 |
8-K: Unregistered Sales of Equity Securities; Amendments to Articles/Bylaws; Change in Fiscal Year +1 more
ADARx Pharmaceuticals, Inc., a corporation organized and existing under and by virtue of the General Corporation Law of the State of Delaware (the “DGCL”), does hereby certify that: |
Loading...